Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are dysregulated in a variety of disease states, suggesting that this newly discovered class of gene expression repressors may be viable therapeutic targets. A microarray of miRNA changes in ALS-model superoxide dismutase 1 (SOD1)(G93A) rodents identified 12 miRNAs as significantly changed. Six miRNAs tested in human ALS tissues were confirmed increased. Specifically, miR-155 was increased 5-fold in mice and 2-fold in human spinal cords. To test miRNA inhibition in the central nervous system (CNS) as a potential novel therapeutic, we developed oligonucleotide-based miRNA inhibitors (anti-miRs) that could inhibit miRNAs throughout the CNS and in the periphery. Anti-miR-155 caused global derepression of targets in peritoneal macrophages and, following intraventricular delivery, demonstrated widespread functional distribution in the brain and spinal cord. After treating SOD1(G93A) mice with anti-miR-155, we significantly extended survival by 10 days and disease duration by 15 days (38%) while a scrambled control anti-miR did not significantly improve survival or disease duration. Therefore, antisense oligonucleotides may be used to successfully inhibit miRNAs throughout the brain and spinal cord, and miR-155 is a promising new therapeutic target for human ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“miRNAs are increasingly recognized as key regulators in ALS pathophysiology, including mitochondrial integrity and neuroinflammation, with miR-155 and miR-206 demonstrating pivotal roles in SOD1G93A models [48,49,50,51].”
From Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis (2026) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Inhibiting miR-155 significantly delays disease progression in SOD1 G93A mice (Koval et al., 2013;Butovsky et al., 2015).”
From MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models (2017) · cites this paper as Koval et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“Work from our lab and others found that miR-155, a glialenriched miRNA, is upregulated in the spinal cords of end-stage ALS model (SOD1 G93A ) mice and human autopsy (Koval et al., 2013;Butovsky et al., 2015).”
From MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models (2017) · cites this paper as Koval et al., 2013
In the citing paper
“Targeting miR-155 in microglia has shown to be a benefit in models of ALS84,195 and is currently being pursued as a possible therapeutic strategy.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [195]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948 · cited 1×
“Since their discovery in 1993 (1), microRNAs (miRNAs) have emerged as key regulators in numerous physiological and pathological processes.”
A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204 · cited 1×
“Anti-miRs have been used safely and effectively in the periphery in recent human clinical trials [NCT00688012 and NCT00979927 (20)], and CSF infusion of antisense oligonucleotides designed to lower mRNA has recently been applied to patients with ALS (21).”
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,067
Inositol phosphatase SHIP1 is a primary target of miR-155
O'Connell, R. M., Chaudhuri, A. A., Rao, D. S., & Baltimore, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902636106 · Cited by 826 · cited 3×
“Furthermore, quantification of one of these targets, SHIP1, across the CNS demonstrated a significant increase over saline in all areas assayed (Fig.”
microRNA-155 Regulates the Generation of Immunoglobulin Class-Switched Plasma Cells
Vigorito, E., Perks, K. L., Abreu-Goodger, C., Bunting, S., Xiang, Z., Kohlhaas, S., Das, P. P., Miska, E. A., Rodriguez, A., Bradley, A., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.10.009 · Cited by 763
Current hypotheses for the underlying biology of amyotrophic lateral sclerosis
Rothstein, J. D. (2009) · Annals of Neurology · doi:10.1002/ana.21543 · Cited by 703 · cited 1×
“Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig’s Disease) is a fatal adult-onset neurodegenerative disease characterized by the selective loss of motor neurons in the spinal cord and brain leading to stiffness, severe muscle weakness and death because of respiratory failure typically within 3–5 years of…”
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationJunker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R., Lassmann, H., Wekerle, H., Hohlfeld, R., & Meinl, E. (2009) · Brain · doi:10.1093/brain/awp300 · Cited by 595 · cited 1×
“Our data clearly identify miR-155 as a promising therapeutic target for ALS and may potentially apply more broadly to neurological disorders where miR-155 is increased including multiple sclerosis (23) and in glioblastoma (24).”
Research works printed but not linked: 2
- Esau, C. (2010) In: Keystone Symposia: Diabetes (Z6). Whistler: British Columbia Canada.
- D'Urso, P.I., D'Urso, O.F., Storelli, C., Mallardo, M., Gianfreda, C.D., Montinaro, A., Cimmino, A., Pietro, C. and Marsigliante, S. (2012) miR-155 4134 Human Molecular Genetics, 2013, Vol. 22, No. 20
Cited by
Items 101–200 of 243
The Potential Role of Amygdaloid MicroRNA-494 in Alcohol-Induced Anxiolysis
Teppen, T. L., Krishnan, H. R., Zhang, H., Sakharkar, A. J., & Pandey, S. C. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.028 · Cited by 45
MicroRNAs: Newcomers into the ALS Picture
Volonte, C., Apolloni, S., & Parisi, C. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527314666150116125506 · Cited by 42
Transcriptomic profiling of platelet senescence and platelet extracellular vesicles
Pienimaeki‐Roemer, A., Konovalova, T., Musri, M. M., Sigrüener, A., Boettcher, A., Meister, G., & Schmitz, G. (2016) · Transfusion · doi:10.1111/trf.13896 · Cited by 45
Oligonucleotide-based therapy for neurodegenerative diseases
Magen, I., & Hornstein, E. (2014) · Brain Research · doi:10.1016/j.brainres.2014.04.005 · Cited by 41
Pomper, N., Liu, Y., Hoye, M. L., Dougherty, J. D., & Miller, T. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-61307-5 · Cited by 39
Self-citationAboulhoda, B. E., Rashed, L. A., Ahmed, H. R., Obaya, E. M. M., Ibrahim, W., Alkaffas, M., El‐Aal, S. A. A., & ShamsEldeen, A. M. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30283 · Cited by 41
Approaches to gene modulation therapy for ALS
Meijboom, K. E., & Brown, R. H. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01285-w · Cited by 38
“Newborn MN-P517L/Δ14 mice received a single ICV dose of 20 μg of ION363.”
BackgroundInfluentialVulnerability of microRNA biogenesis in FTD–ALS
Eitan, C., & Hornstein, E. (2016) · Brain Research · doi:10.1016/j.brainres.2015.12.063 · Cited by 41
Mitropoulos, K. A., Κάτσιλα, Θ., Patrinos, G. P., & Pampalakis, G. (2018) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2017.0183 · Cited by 39
“Inhibition of miR-155 prolongs survival in SOD1 G93A mice (Koval et al., 2013), and it is found to be increased fivefold and twofold in mice and human spinal cords, respectively (Koval et al., 2013).”
Jagaraj, C. J., Parakh, S., & Atkin, J. D. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.581950 · Cited by 40
“Specific micro-RNAs were upregulated; miR-27a, miR-338-3p, miR-155, whereas other micro-RNAs were downregulated in ALS patients; miR-142-5p, and miR-34a (Koval et al., 2013; Waller et al., 2017; Ricci et al., 2018; Li C. et al., 2019).”
BackgroundClinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?
Nicholson, K. A., Cudkowicz, M., & Berry, J. D. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0341-2 · Cited by 38
“, micro-RNA), a promising marker of inflammation, is found to be upregulated in patients with ALS and may be predictive or prognostic [39–41].”
MicroRNAs in central nervous system disorders: current advances in pathogenesis and treatment
Hussein, M., & Magdy, R. (2021) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-021-00289-1 · Cited by 40
“miR-27a, miR-34a, miR155, miR-142-5p, and miR-338-3p were indicated as novel biomarkers and potential therapeutic targets in ALS [63, 64].”
BackgroundInfluentialXu, X., Đenić, A., Jordan, L. R., Wittenberg, N. J., Warrington, A. E., Wootla, B., Papke, L. M., Zoecklein, L. J., Yoo, D., Shaver, J., et al. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.020727 · Cited by 41
DeLoach, A., Cozart, M. A., Kiaei, A., & Kiaei, M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1067197 · Cited by 39
“In another study, anti-miR155 injection into the brain ventricle extended the survival of G93A mice by 10 days and prolonged the disease duration by 38% [29].”
BackgroundCurrent developments in gene therapy for amyotrophic lateral sclerosis
Scarrott, J. M., Herranz-Martín, S., Alrafiah, A., Shaw, P. J., & Azzouz, M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1044894 · Cited by 36
“In this study, specific ASOs designed to decrease the levels of miRNA-155 in SOD1-G93A mice prolonged survival in this murine model in comparison to scrambled control anti-miRNA [79].”
BackgroundMaximizing the Survival of Amyotrophic Lateral Sclerosis Patients: Current Perspectives
Khairoalsindi, O. A., & Abuzinadah, A. R. (2018) · Neurology Research International · doi:10.1155/2018/6534150 · Cited by 37
Olawade, D. B., Rashad, I., Egbon, E., Teke, J., Ovsepian, S. V., & Boussios, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104929 · Cited by 37
“RNA-seq analysis revealed the restored expression of over 300 dysregulated genes involved in neuroinflammation and neuronal survival [92].”
Biomarker development for C9orf72 repeat expansion in ALS
Mendez, E. F., & Sattler, R. (2014) · Brain Research · doi:10.1016/j.brainres.2014.09.041 · Cited by 36
MotomiRs: miRNAs in Motor Neuron Function and Disease
Hawley, Z. C. E., Campos‐Melo, D., Droppelmann, C. A., & Strong, M. J. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00127 · Cited by 40
Yardeni, T., Fine, R., Joshi, Y., Gradus, T., Kozer, N., Reichenstein, I., Yanowski, E., Nevo, S., Weiss-Tishler, H., Eisenberg‐Bord, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-17878-x · Cited by 37
Non-Coding RNAs as Sensors of Oxidative Stress in Neurodegenerative Diseases
Gámez‐Valero, A., Guisado-Corcoll, A., Herrero‐Lorenzo, M., Solaguren‐Beascoa, M., & Martí, E. (2020) · Antioxidants · doi:10.3390/antiox9111095 · Cited by 35
“For example, miR-27a, miR-34a, miR-155, miR-142-5p, and miR-338-3p have been proposed as biomarkers and potential ALS therapeutic targets, directly or indirectly involved in OS [234,236,238,239].”
BackgroundmicroRNA 155 up regulation in the CNS is strongly correlated to Down's syndrome dementia
Tili, E., Mezache, L., Michaille, J., Amann, V., Williams, J. M., Vandiver, P., Quiñónez, M., Fadda, P., Mikhail, A. A., & Nuovo, G. J. (2018) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2018.03.006 · Cited by 33
RNA Deregulation in Amyotrophic Lateral Sclerosis: The Noncoding Perspective
Laneve, P., Tollis, P., & Caffarelli, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910285 · Cited by 32
Gomes, C., Sequeira, C., Likhite, S. B., Dennys, C. N., Kolb, S. J., Shaw, P. J., Vaz, A. R., Kaspar, B. K., Meyer, K., & Brites, D. M. T. O. (2022) · Cells · doi:10.3390/cells11071186 · Cited by 33
“However, to be sure that our modulation with pre-miR-146a did not contribute to the upregulation of miR-155, which was found elevated in the spinal cord of fALS and sALS patients [85] and associated with decreased mSOD1 mouse survival [42], we decided to investigate whether changes were produced on miRNA-155 by the pr…”
BackgroundSilencing a Multifunctional microRNA Is Beneficial for Stroke Recovery
Roitbak, T. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00058 · Cited by 32
“Inhibition prolongs survival and ameliorates disease in SOD1 mice (Koval et al., 2013; Butovsky et al., 2015).”
BackgroundMicro RNA s as regulators of cell death mechanisms in amyotrophic lateral sclerosis
Gagliardi, D., Comi, G. P., Bresolin, N., & Corti, S. P. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13976 · Cited by 35
“spinal cord, with a fivefold increase in rodent and twofold increase in patients samples.(40) Anti‐miR‐155 prompted generalized de‐repression of mRNA targets in peritoneal macrophages and was found to”
BackgroundResultObora, K., Onodera, Y., Takehara, T., Frampton, J. P., Hasei, J., Ozaki, T., Teramura, T., & Fukuda, K. (2017) · Scientific Reports · doi:10.1038/srep43604 · Cited by 32
Awad, H., Bratasz, A., Nuovo, G. J., Burry, R. W., Meng, X., Kelani, H., Brown, M., Ramadan, M. E., Williams, J., Bouhliqah, L., et al. (2018) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2018.06.002 · Cited by 30
Regulation of Skeletal Muscle Development and Disease by microRNAs
Liu, N., & Bassel‐Duby, R. (2014) · Results and problems in cell differentiation · doi:10.1007/978-3-662-44608-9_8 · Cited by 29
Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases
Bishop, K. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.015 · Cited by 30
“Mutations in SOD1 account for approximately 12% of familial ALS cases and data suggest that SOD1 may also be pathologic in sporadic ALS (Gruzman, 2007; Bosco, 2010; Pokrishevsky, 2012).”
BackgroundInfluentialRNA-Targeted Therapies and Amyotrophic Lateral Sclerosis
Mathis, S., & Masson, G. L. (2018) · Biomedicines · doi:10.3390/biomedicines6010009 · Cited by 33
Cell death cascade and molecular therapy in ADAR2-deficient motor neurons of ALS
Yamashita, T., & Kwak, S. (2018) · Neuroscience Research · doi:10.1016/j.neures.2018.06.004 · Cited by 29
Immune Regulation of Tissue Repair and Regeneration via miRNAs—New Therapeutic Target
Piotto, C., Julier, Z., & Martino, M. M. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00098 · Cited by 29
MicroRNAs and Regeneration in Animal Models of CNS Disorders
Roitbak, T. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02777-6 · Cited by 28
The Yin and Yang of nucleic acid-based therapy in the brain
Gustincich, S., Zucchelli, S., & Mallamaci, A. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.11.001 · Cited by 33
“After continuous intra-ventricular administration, treated mice showed extended survival and prolongued disease duration (38%) (Koval et al., 2013).”
Aggio‐Bruce, R., Chu‐Tan, J. A., Wooff, Y., Cioanca, A. V., Schümann, U., & Natoli, R. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02158-z · Cited by 31
“Similar to the findings presented here, Koval et al. (2013) previously showed that administration of fluorescently tagged anti-miR-155 administration to the lateral ventricle of the brain induced cell specific uptake by neurons, microglia and astrocytes, leading to the regulation of…”
ResultWang, L., & Zhang, L. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04773-z · Cited by 28
RNA-targeted Therapeutics for ALS
Reddy, L. V., & Miller, T. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0344-z · Cited by 28
Self-citationVersatile role of miR-24/24-1*/24-2* expression in cancer and other human diseases.
Mukherjee, S., Shelar, B., & Krishna, S. (2022) · PubMed · Cited by 36
Diagnostic Circulating miRNAs in Sporadic Amyotrophic Lateral Sclerosis
Panio, A., Cava, C., D’Antona, S., Bertoli, G. R., & Porro, D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.861960 · Cited by 25
Marton, S., Miquel, E., Acosta-Rodríguez, J., Fontenla, S., Libisch, G., & Cassina, P. (2023) · ASN NEURO · doi:10.1177/17590914231197527 · Cited by 27
Paola, E. D., Verdile, V., & Paronetto, M. P. (2018) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.12.001 · Cited by 25
Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets
Jiang, Z., Wang, Z., Wei, X., & Yu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1059994 · Cited by 24
Genomic and transcriptomic advances in amyotrophic lateral sclerosis
Rizzuti, M., Sali, L., Melzi, V., Scarcella, S., Costamagna, G., Ottoboni, L., Quetti, L., Brambilla, L., Papadimitriou, D. A., Verde, F., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102126 · Cited by 24
“Koval ’ s team explored the therapeutic potential of antagonizing miR-155 in the CNS, demonstrating for the first time that oligonucleotide-based miRNA inhibitors could successfully inhibit miRNA throughout the CNS after intraventricular delivery (Koval et al., 2013).”
BackgroundExosomal Proteins and miRNAs as Mediators of Amyotrophic Lateral Sclerosis
Chen, Q. Y., Wen, T., Wu, P., Jia, R., Zhang, R., & Dang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.718803 · Cited by 25
Rodríguez, M., & Mahy, N. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867324666161123091314 · Cited by 21
Kim, K. Y., Kim, Y. R., Choi, K. W., Lee, M., Lee, S., Im, W., Shin, J.-Y., Kim, J. Y., Hong, Y., Kim, M., et al. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00203-4 · Cited by 33
Bono, N., Fruzzetti, F., Farinazzo, G., Candiani, G., & Marcuzzo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125671 · Cited by 22
“For instance, anti-miRNA-155 reduced neuroinflammation and prolonged survival in ALS-model mice, while miRNA-206 upregulation improved neuromuscular junction regeneration [123].”
Increased ISGylation in Cases of TBI-Exposed ALS Veterans
Schwartzenburg, J., Juncker, M. A., Reed, R. E., & Desai, S. D. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly129 · Cited by 23
Cipollina, G., Serej, A. D., Nolfi, G. D., Gazzano, A., Marsala, A., Spatafora, M. G., & Peviani, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217923 · Cited by 20
“In line with this observation, treatment with a miR-155 inhibitor partially restored homeostatic microglia genes and prolonged survival of SOD1 mice [45,46].”
ResultHosaka, T., Tsuji, H., & Tamaoka, A. (2021) · Processes · doi:10.3390/pr9091667 · Cited by 20
Exosomal non-coding RNAs: gatekeepers of inflammation in autoimmune disease
Saadh, M. J., Allela, O. Q. B., Al-Hussainy, A. F., Baldaniya, L., Rekha, M. M., Nathiya, D., Kaur, P., Aminov, Z., Sameer, H. N., Hameed, H. G., et al. (2025) · Journal of Inflammation · doi:10.1186/s12950-025-00443-z · Cited by 22
“Notably, among the aforementioned miRNAs, miR-155, miR-146b, and miR-125b are recognized as integral constituents of the innate immune system [166–168].”
MicroRNAs and nervous system diseases: network insights and computational challenges
Wang, J., Cao, Y., Lu, X., Wang, T., Li, S., Kong, X., Bo, C., Li, J., Wang, X., Ma, H., et al. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz032 · Cited by 18
Nógrádi, B., Nógrádi-Halmi, D., Erdélyi-Furka, B., Kádár, Z., Csont, T., & Gáspár, R. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02055-7 · Cited by 20
“Moreover, treatment with the oligonucleotide-based anti-miRNA-155 inhibitor has been shown to prolong the survival of SOD1 G93A mice [23].”
BackgroundAutophagy in spinal muscular atrophy: from pathogenic mechanisms to therapeutic approaches
Rashid, S., & Dimitriadi, M. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1307636 · Cited by 18
Ashique, S., Kumar, N., Mishra, N., Muthu, S., Rajendran, R. L., Chandrasekaran, B., Obeng, B. F., Hong, C. M., Krishnan, A., Ahn, B., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155451 · Cited by 18
Peplow, P., & Martinez, B. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.322431 · Cited by 20
“…mice Lumbar spinal cord Presymptomatic 70 d Symptomatic 90 d RT-PCR miR-29a Zhou et al., 2013 SOD1(G93A) mice Spinal cord 95, 108, 122 d RT-PCR miR-9 Koval et al., 2013 SOD1(G93A) mice Spinal cord End stage Microarray analysis miR-17, miR-19b, miR20a, miR-24-2-5p, miR106a, miR-142-3p,…”
BackgroundResultInfluentialmicroRNA as a new agent for regulating neuronal glutathione synthesis and metabolism
Kinoshita, C., Aoyama, K., & Nakaki, T. (2015) · AIMS molecular science · doi:10.3934/molsci.2015.2.124 · Cited by 16
ALS, a cellular whodunit on motor neuron degeneration
Karagiannis, P., & Inoue, H. (2020) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2020.103524 · Cited by 17
Zhu, Y., Wang, F., Xia, Y., Wang, L., Lin, H., Zhong, T., & Wang, X. (2024) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0043 · Cited by 15
Aberrant Rna Homeostasis in Amyotrophic Lateral Sclerosis: Potential for New Therapeutic targets?
Donnelly, C. J., Grima, J. C., & Sattler, R. (2014) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.36 · Cited by 18
Avitabile, C., Cimmino, A., & Romanelli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006594 · Cited by 14
Recent Advances in the Roles of MicroRNA and MicroRNA-Based Diagnosis in Neurodegenerative Diseases
Zhang, J., Chen, Z., Chen, H., Deng, Y., Li, S., & Jin, L. J. (2022) · Biosensors · doi:10.3390/bios12121074 · Cited by 13
Koike, Y. M., & Onodera, O. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1131758 · Cited by 13
“Indeed, the anti-miR-155 could significantly prolong the survival time in SOD1G93A mice (Koval et al., 2013).”
BackgroundBaumert, B., Sobuś, A., Gołąb-Janowska, M., Paczkowska, E., Łuczkowska, K., Rogińska, D., Zawiślak, A., Milczarek, S., Osękowska, B., Pawlukowska, W., et al. (2020) · Cells · doi:10.3390/cells9081822 · Cited by 12
“have reported that this molecule is overexpressed in the spinal cords of ALS patients and in SOD1G93A mice, and proposed miR-155 not only as a marker of the disease but also as a potential therapeutic target [50].”
BackgroundEmerging role of microRNAs in the pathogenesis of amyotrophic lateral sclerosis
Dilmaghani, N. A., Hussen, B. M., Nateghinia, S., Taheri, M. N., & Ghafouri‐Fard, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00697-5 · Cited by 12
Regulation of LncRNAs and microRNAs in neuronal development and disease
Xuan, C., Yang, E., Zhao, S., Xu, J., Li, P., Zhang, Y., Jiang, Z., & Ding, X. (2023) · PeerJ · doi:10.7717/peerj.15197 · Cited by 15
Neto, J. R. M., de Souza, G. F., dos Santos, V. M., Paranhos, L. H., Ribeiro, G. D., Magalhães, R. S. S., Queiroz, D. D., & Eleuthério, E. C. A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05067-1 · Cited by 13
“The pro-inflammatory miR-155 was found increased in a mice model of fALS [133].”
miR-23a suppression accelerates functional decline in the rNLS8 mouse model of TDP-43 proteinopathy
Tsitkanou, S., Gatta, P. A. D., Abbott, G., Wallace, M. A., Lindsay, A., Gerlinger‐Romero, F., Walker, A. K., Foletta, V. C., & Russell, A. P. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105559 · Cited by 10
Shaw, C. A. (2017) · Wiley eBooks · doi:10.1002/9781118634523.refs · Cited by 10
Therapeutic targeting of RNA for neurological and neuromuscular disease
Bubenik, J. L., Scotti, M. M., & Swanson, M. S. (2024) · Genes & Development · doi:10.1101/gad.351612.124 · Cited by 12
“…by recruiting RNase H (gapmers) (Monia et al. 1993; Agrawal et al. 1997); (3) silence miRNAs using antagomiRs or anti-miRs (Krützfeldt et al. 2005; Koval et al. 2013; González-Martínez et al. 2023); and (4) enhance expression of wild-type allele RNA transcript levels by inhibiting natural…”
Lee, Y., Boschian, C., & Ko, K. (2025) · RNA Biology · doi:10.1080/15476286.2025.2558631 · Cited by 10
In vivo and ex vivo gene therapy for neurodegenerative diseases: a promise for disease modification
Ebrahimi, P., Davoudi, E., Sadeghian, R., Zadeh, A. Z., Razmi, E., Heidari, R., Morowvat, M. H., & Sadeghian, I. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03141-4 · Cited by 8
“For instance, increased expression of miRNA 155 has been observed in SOD1 mice and human ALS spinal cord samples, and suppressing this miRNA using ASOs in SOD1 mice led to prolonged survival (Koval et al. 2013).”
Choi, Y. J., Kim, C., Choi, E. W., Lee, S. H., Chae, M. K., Jun, H. O., Kim, B., Yoon, J. S., & Jang, S. Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270416 · Cited by 8
Phylogenetic analysis of microRNA biomarkers for amyotrophic lateral sclerosis
Wang, H. (2021) · Biocell · doi:10.32604/biocell.2021.014343 · Cited by 7
“The survival time of SOD1-G93A mice was significantly extended by treatment with anti-miR-155 compared with control cases (Koval et al., 2013).”
BackgroundThe Influence of Extracellular RNA on Cell Behavior in Health, Disease, and Regeneration
Huleihel, L., Scarritt, M. E., & Badylak, S. F. (2017) · Current Pathobiology Reports · doi:10.1007/s40139-017-0121-2 · Cited by 7
Translational Research on Amyotrophic Lateral Sclerosis (ALS): The Preclinical SOD1 Mouse Model
Mina, M., Konsolaki, E., & Zagoraiou, L. (2018) · Journal of Translational Neurosciences · doi:10.21767/2573-5349.100022 · Cited by 6
SMALL NONCODING RNA AS PERSPECTIVE BIOMARKERS: BIOGENESIS AND THERAPEUTIC STRATIGIES
Владимирович, Т. В., Ivanova, S. А., Serebrov, V. Y., & Buhareva, M. B. (2016) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2016-2-112-126 · Cited by 8
Wang, R., Chen, L., Zhang, Y., Sun, B., & Liang, M. (2024) · Life · doi:10.3390/life14091125 · Cited by 6
“…stage by RT-PCR, whereas the expression of cytokine signaling pathway inhibitor 1, its direct target, was decreased. miR-155 is markedly increased in the spinal cord of asymptomatic SOD1 (G93A) mice, indicating that the upregulation of miR-155 occurs before the onset of the disease [48,71].”
BackgroundThe Role of Non-Coding RNAs in ALS
Falduti, A., Giovinazzo, A., Feudo, E. L., Rocca, V., Brighina, F., Messina, A. A., Conforti, F. L., & Iuliano, R. (2025) · Genes · doi:10.3390/genes16060623 · Cited by 5
“Furthermore, miR-155, by binding and inhibiting the mRNA encoding the suppressor of cytokine signaling 1 (SOCS1), has been shown to promote the secretion of pro-inflammatory cytokines [31,32,71].”
An Epigenetic Spin to ALS and FTD
Ebbert, M., Lank, R. J., & Belzil, V. (2018) · Advances in neurobiology · doi:10.1007/978-3-319-89689-2_1 · Cited by 6
Chávez, J. C. P., Dobricic, M., McGrath, M., O’Connor, C., McGuire, T. K., Maughan, J., Dervan, A. G., Dixon, J. E., Kearney, C. J., Browne, S., et al. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.02.004 · Cited by 10
“Evidence from several in vitro and in vivo studies indicate that neurons in the central and peripheral nervous systems regain regenerative potential following miRNA-155 inhibition [33 – 36].”
InfluentialNucleic Acid-Based Strategies to Treat Neurodegenerative Diseases
Panda, S., Chatterjee, O., & Chatterjee, S. (2023) · Springer eBooks · doi:10.1007/978-981-19-8520-1_4 · Cited by 6
Azam, H. M. H., Mumtaz, M., Rödiger, S., Schierack, P., Hussain, N., & Ambreen, A. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08419-w · Cited by 5
Non-coding RNAs in neurodegeneration: an axis-based, evidence-tiered mechanistic synthesis
Ahim, S. S., Bandegi, M., Ghanbarzadeh, E., & Heidarzadehpilehrood, R. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100458 · Cited by 4
Multimodal strategies for diagnosis, stratification, and therapeutic monitoring in ALS
López‐Blanch, R., Oriol‐Caballo, M., Estrela, J. M., & Obrador, E. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106727 · Cited by 3
Wang, J., Li, X., Yang, F., Guo, P., Ren, C., Duan, Z., Bi, M., Kong, Y., Zhang, Y., & Lu, J. (2025) · Analytical Biochemistry · doi:10.1016/j.ab.2025.115969 · Cited by 3
Targeting Macrophage for the Treatment of Amyotrophic Lateral Sclerosis
Li, L., Liu, J., & She, H. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666190409103831 · Cited by 3
Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis
Ryu, I. S., Ha, D.-I., Jung, Y.-J., Lee, H. J., Kim, I., Lim, Y. N., Min, H. S., Kim, S. H., Yoon, I., Cho, H.-J., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020615 · Cited by 2
“…ALS, with important implications for developing therapeutic strategies [47]. miRNAs are increasingly recognized as key regulators in ALS pathophysiology, including mitochondrial integrity and neuroinflammation, with miR-155 and miR-206 demonstrating pivotal roles in SOD1 G93A models [48–51].”
Kumar, A., Shukla, S., Rai, A., Pathak, P., & Narayan, K. P. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-04042-2 · Cited by 2
Antecedent enhancer activity predicts future susceptibility to seizures in mice
Boros, B. D., Gachechiladze, M. A., Guo, J., Galloway, D. A., Mueller, S. M., Shabsovich, M., Yen, A., Chen, X., Cammack, A. J., Shen, T., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-65346-2 · Cited by 2
Self-citationApplications and Developments of Gene Therapy Drug Delivery Systems for Neurological Disorders
Nguyen, N. H., Nguyen‐Thi, P., Nguyen, T. T., Bui, V. K. H., Nguyen, N. T. T., & Giau, V. V. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400269 · Cited by 3
MicroRNAs Fine-Tune Brain and Body Communication in Health and Disease
Henshall, D. C. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-89525-8_12 · Cited by 2
Ageing at Molecular Level: Role of MicroRNAs
Yadav, S., Sarkar, S., Pandey, A. K., & Singh, T. (2023) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-21410-3_9 · Cited by 2
miR-146a is a pleiotropic regulator of motor neuron degeneration
Galloway, D. A., Patterson, H. L., Hoye, M. L., Shen, T., Shabsovich, M., Schoch, K. M., Ly, C. V., & Mill, J. S. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2526314123 · Cited by 1
IsomiR utility in amyotrophic lateral sclerosis prognostication
Cohen, Y., Sinai, I., Magen, I., Danino, Y. M., Wuu, J., Malaspina, A., Benatar, M. G., & Hornstein, E. (2025) · Med · doi:10.1016/j.medj.2025.100928 · Cited by 3
Nwokwu, C. D. U., Nestorova, G. G., Walker, M. H., & Louis, S. J. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11384-4 · Cited by 1
“For instance, miR-155 upregulation has been implicated in amyotrophic lateral sclerosis (ALS), and its inhibition slowed down disease progression in pre-clinical models [54 ].”
MicroRNA Implications in Neurodegenerative Disorders
Chaudhuri, A. D., & Yelamanchili, S. V. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_21 · Cited by 1
Patil, K. S., & Møller, S. G. (2019) · Springer eBooks · doi:10.1007/978-3-319-55530-0_58 · Cited by 1
Metadata
- Authors
- Koval, E. D., Shaner, C., Zhang, P., du Maine, X., Fischer, K., Tay, J., Chau, B. N., Wu, G. F., & Miller, T. M.
- Affiliations
- Washington University in St. Louis (US)
- Regulus Therapeutics (United States) (US)
- Corresponding author
- Miller, Timothy M.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-06-04
- Volume
- 22
- Issue
- 20
- Pages
- 4127-4135
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC3781640
- OpenAlex
- W2106430667
- Cited by
- 236
- References
- 27
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 11 · 2023: 15 · 2022: 11 · 2021: 15 · 2020: 29 · 2019: 13 · 2018: 30 · 2017: 22 · 2016: 17 · 2015: 27 · 2014: 19 · 2013: 2
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Dana Foundation
- Massachusetts General Hospital
- Edward Mallinckrodt, Jr. Foundation
- National Institutes of Health
- School of Medicine, Stanford University
- National Institute of Neurological Disorders and Stroke (F31NS077781, K08NS062138, K08NS074194, R01NS078398)
- Robert Packard Center for ALS Research, Johns Hopkins University
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Keywords
- miR-155, amyotrophic lateral sclerosis, anti-miR oligonucleotides, microRNA inhibition, SOD1 G93A mice, survival extension, peritoneal macrophages, spinal cord, therapeutic target, antisense oligonucleotides
- MeSH terms
- Adult, Aged, Amyotrophic Lateral Sclerosis, Animals, Brain, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Middle Aged, Spinal Cord, Superoxide Dismutase, Case-Control Studies, Oligonucleotides, Antisense, MicroRNAs, Mice, Rats, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.